Granisetron Crescent Pharma

Granisetron Crescent Pharma is an oral formulation containing the active ingredient granisetron. It is a prescription‑only 5‑HT3 receptor antagonist marketed in the European Union. The product is used to manage nausea and vomiting associated with chemotherapy and surgery, acting by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract.

Granisetron Crescent Pharma is indicated for the prevention and treatment of nausea and vomiting in specific clinical settings.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV). - Treatment of acute CINV episodes. - Prevention of postoperative nausea and vomiting (PONV). - Adjunct therapy for radiation‑induced nausea when chemotherapy is also administered. - Use in patients who have not responded adequately to other antiemetics.

Granisetron Crescent Pharma may cause a range of side effects, most of which are mild and transient.

Common: - Headache - Constipation - Fatigue or drowsiness - Dizziness - Transient mild abdominal discomfort

Serious: - Severe allergic reaction (rash, itching, swelling, difficulty breathing) - Cardiac arrhythmia or prolonged QT interval (rare) - Severe constipation leading to bowel obstruction - Persistent or worsening dizziness with visual disturbances

When prescribing Granisetron Crescent Pharma, clinicians should consider several safety factors.

- Assess patient history for cardiac conduction disorders or prolonged QT interval. - Use caution in patients with severe hepatic impairment, as metabolism may be reduced. - Monitor for signs of hypersensitivity, especially after the first dose. - Evaluate the need for dose adjustment in elderly patients. - Discuss potential constipation and advise patients to maintain adequate hydration and fiber intake. - Consider alternative antiemetics if the patient is taking other QT‑prolonging drugs.

Granisetron Crescent Pharma can interact with other medications, influencing efficacy or safety.

Avoid: - Other 5‑HT3 antagonists used concurrently, which may increase risk of cardiac effects. - Drugs known to significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).

Use with caution: - Anticholinergic agents that may exacerbate constipation. - CYP3A4 inhibitors or inducers, although granisetron metabolism is limited, monitoring is advised. - Opioids, as combined use may increase the risk of dizziness or sedation. - Diuretics, due to potential electrolyte shifts affecting cardiac repolarization.